Low grade inflammation with high blood sugar increases death risk
China: Serum hs-CRP can predict 10-year all-cause mortality in Chinese adults with hyperglycemia, according to a recent study in the journal Diabetes Research and Clinical Practice. This suggests that there is a need for giving more attention on the impact of low-grade inflammation on mortality in people with type 2 diabetes.
Studies in the past have established high sensitivity C-reactive protein (hsCRP), a biomarker of inflammation, as an independent predictor for CAD.
Guangwei Li, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, and colleagues examine whether high-sensitivity C-reactive protein (hs-CRP) can predict all-cause death in Chinese adults with hyperglycemia. A high level of CRP in the blood is a marker of inflammation.
The researchers recruited 237 diabetes and 49 prediabetes evolved from the participants with impaired glucose tolerance in the original Da Qing Diabetes Study. Blood hs-CRP level was measured at 2006. Ten-year death outcome was traced from 2006 to 2016. The association between hs-CRP level and the risk of all-cause death occurred over the subsequent 10 years was analyzed using the Cox model.
Key findings of the study include:
- During the follow-up, death occurred in 36 (37.9%) subjects in the highest hs-CRP tertile group (hs-CRP > 2.16 mg/L) and 19 (20.0%) in the lowest hs-CRP tertile group (hs-CRP < 0.82 mg/L).
- The corresponding incidence of all-cause death (per 1,000 person-years) was 44.7 and 21.6 in the two groups respectively.
- The highest hs-CRP tertile was associated with the increased risk of all-cause death significantly (hazard ratio 1.88) after controlling for traditional risk factors.
"Serum hs-CRP was predictive of 10-year all-cause death in Chinese adults with hyperglycemia, suggesting the impact of low-grade inflammation on mortality deserves more attention," concluded the authors.
The research titled, "Prediction of 10-year mortality using hs-CRP in Chinese people with hyperglycemia: Findings from the Da Qing diabetes prevention outcomes study," is published in the journal Diabetes Research and Clinical Practice.
DOI: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(21)00021-8/fulltext
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.